Preclinical models for pulmonary disease and drug delivery
map

Our in vitro and ex vivo capabilities are broad and provide a translational platform for the screening and testing of candidate compounds and target pathways.

Projects can be tailored to client needs, conducted using cells and tissues from healthy and/or diseased sheep, and may include cellular, biochemical and molecular analyses. Allergenix has the expertise as well as access to world-class facilities and services through their partnership with the Hudson Institute of Medical Research to enable these studies.

1. Isolated primary cells

  • immune cells – blood/lymph node/BAL macrophages, lymphocytes, dendritic cells
  • airway cells – epithelial cells, fibroblasts, airway smooth muscle
  • monolayers, cell co-cultures

 

Slide12. Tissue explants

  • endobronchial biopsy samples
  • tissue explants; tracheal, bronchial

 

3. Precision-cut lung slices (PCLS)

  • airway contractility
  • active/passive treatments

 

Measurements/biomarkers: cell and tissue-specific effects

  • tissue structure, cell distribution/structure – histology; histochemistry; immunostaining (surface, intracellular, tissue elements); confocal microscopy; electron microscopy
  • immune cell/mediator analyses; cellular, biochemical and molecular analyses
  • cell phenotype, activation, function – flow cytometry
  • proteins, cytokines, biomarker detection – ELISA; Western Blot
  • gene expression analysis – real-time RT-PCR; microarray; single cell profiling (Fluidigm system)

 

 

Pulmonary drug administration

Allergenix respiratory disease models

In vivo capabilities